Zhejiang Tianyu Pharmaceutical (300702.SZ): Hydrobromide Quetiapine Tablets and others are expected to be selected for the twelfth batch of national centralized drug procurement.

Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., participated in the bidding work for the 12th batch of national centralized procurement of medicines organized by the National Organization for Drug Procurement Office (referred to as "Procurement Office"). According to the "Proposed Selected Results Announcement for the 12th Batch of National Organized Drug Centralized Procurement" released by the Procurement Office on July 31, 2026, on the Shanghai Sunshine Pharmaceutical Procurement Network, the company's productstizanidine hydrochloride tablets and tolvaptan tabletsare proposed for selection in this centralized procurement. The procurement cycle for the proposed selected products will be from the execution date of the selected results until December 31, 2029. If the subsequent procurement contract is successfully signed and implemented, it is expected to further enhance the sales volume and market share of these products, thereby strengthening the company's brand influence.